8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2015

IMS Health Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-36381	27-1335689
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)

 83 Wooster Heights Road
Danbury, CT 06810
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (203) 448-4600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 27, 2015 the Board of Directors of IMS Health Holdings, Inc. (the “Company”) increased the size of the Board from seven to eight members and elected Karen Katen as director of the Company upon the recommendation of the Nominating and Corporate Governance Committee.  Ms. Katen will serve as a Class II director, which class will stand for re-election at the 2016 annual meeting of stockholders.  The Board of Directors also appointed Ms. Katen to serve on the Audit Committee of the Board.  Ms. Katen will participate in the Company’s standard non-employee director compensation program described in the Company’s 2014 proxy statement, filed with the Securities and Exchange Commission on March 3, 2015.  The Company’s press release announcing Ms. Katen’s election is filed herewith as Exhibit 99.1 and is incorporated herein by reference.  

Item 9.01  Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press release, dated March 30, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMS Health Holdings, Inc.
	(Registrant)
Date: March 30, 2015		By:	/s/ Ronald E. Bruehlman
			Name:	Ronald E. Bruehlman
			Title:	Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release, dated March 30, 2015

EX-99.1

Exhibit 99.1

Karen Katen Joins IMS Health Board of Directors

DANBURY, Conn.--(BUSINESS WIRE)--March 30, 2015--IMS Health (NYSE:IMS) announced the appointment of Karen Katen to its board of directors, effective today. A senior pharmaceutical industry executive at Pfizer for more than three decades, Karen retired in 2007 as vice chairman of Pfizer Inc. and president of Pfizer Human Health.

“We are very fortunate to have Karen join our board,” said Ari Bousbib, IMS Health chairman and CEO. “Her extensive experience in life sciences, strong commitment to improving public health and proven leadership in developing and commercializing innovative medicines will be invaluable as we execute our growth strategy and deliver value for customers and shareholders.”

As president of Pfizer’s principal operating group, Pfizer Human Health, from 2005 to 2007, Katen was responsible for the global discovery, development and commercialization of prescription medicines, as well as delivery of innovative human health services. Under her leadership, Pfizer Human Health generated more than $45 billion in annual revenue and developed an industry-leading portfolio, with three of the world’s 25 top-selling medicines and seven therapeutic-area leaders.

Katen currently serves as a director on the boards of Air Liquide, Catamaran Corporation, Harris Corporation and The Home Depot. She chairs the RAND Health Board of Advisors and is a member of the Takeda Global Advisory Board and the Novo Nordisk Advisory Committee. She also serves as a senior advisor to Essex Woodlands, a growth equity healthcare investment company.

Katen holds BA and MBA degrees from the University of Chicago, where she serves as a trustee of the university and as a council member of the Booth School of Business.

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the IMS One™ intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently. More than 10,000 employees drive results for over 5,000 healthcare clients across 100 countries, drawing on information from 100,000 suppliers and insights from more than 55 billion healthcare transactions processed annually. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.

CONTACT:
IMS Health
Media Relations
Tor Constantino, +1-484-567-6732
tconstantino@us.imshealth.com